<DOC>
	<DOCNO>NCT00367276</DOCNO>
	<brief_summary>The purpose study evaluate effect quality life BMI new contraceptive .</brief_summary>
	<brief_title>Study Evaluate Effect Six Cycles Treatment With Combined Oral Contraceptive ( EE 0.30 mg/DRSP 3 mg ) Quality Life .</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Female require contraceptive . Aged 18 35 nonsmoker , age 18 30 smoker . Regular menstrual cycle ( define duration 28 +/ 5 day ) . No Contraindication OC use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Females require contraceptive</keyword>
</DOC>